ROCKVILLE, Md. — August 21, 2025 — Leads & Copy — I-Mab (NASDAQ: IMAB) will participate in investor conferences in September, 2025. The management team is scheduled to attend the Cantor Global Healthcare Conference from September 3-5, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 9:30 AM ET. A webcast of the company presentation will be available on the I-Mab website for 90 days.
I-Mab is focused on developing precision immuno-oncology agents for cancer treatment. The company’s pipeline is led by givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells in the tumor microenvironment and is being developed for first-line metastatic gastric cancers, with potential in other solid tumors.
PJ Kelleher, LifeSci Advisors, +1-617-430-7579, pkelleher@lifesciadvisors.com
IR@imabbio.com
Source: I-Mab
